In view of this, experts of the European Hidradenitis Suppurativa Foundation e.V. (EHSF) agreed that treatment with the TNF-α inhibitor, adalimumab (the only biologic agent approved by both FDA and EMA for moderate-to-severe HS), is probably not associated with an increased risk for/a more severe course of COVID-19 [87]. The gene discussed is TNF; the disease is COVID-19.